Evidence map›Paper›PMID 32032355›Full record

Trial reportPLoS medicine2020

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial.

Jacob Fredsøe, Jan Koetsenruyter, Peter Vedsted, Pia Kirkegaard, Michael Væth, Adrian Edwards, Torben F Ørntoft, Karina D Sørensen, Flemming Bro

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01739062 (Prostate Cancer Risk Assessment Using Genetic Markers in General Practice), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01739062 naactive not recruitingnot on this map

Prostate Cancer Risk Assessment Using Genetic Markers in General Practice

TypeinterventionalSponsorUniversity of AarhusRan2013 to 2031Enrolled5,000ConditionsProstate CancerArmsGenetic risk assessment
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob FredsøeDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-7319-2467
Jan KoetsenruyterResearch Unit for General Practice, The Research Centre for Cancer Diagnosis in Primary Care (Cap), Aarhus University, Aarhus, Denmark.ORCID 0000-0003-4632-5129
Peter VedstedDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Pia KirkegaardDepartment of Public Health, Randers Regional Hospital, Randers, Denmark.ORCID 0000-0003-2099-253X
Michael VæthDepartment of Public Health, Section of Biostatistics, Aarhus University, Aarhus, Denmark.
Adrian EdwardsDivision of Population Medicine, School of Medicine, Cardiff University, Cardiff, United Kingdom.ORCID 0000-0002-6228-4446
Torben F ØrntoftDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Karina D SørensenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.ORCID 0000-0002-4902-5490
Flemming BroResearch Unit for General Practice, The Research Centre for Cancer Diagnosis in Primary Care (Cap), Aarhus University, Aarhus, Denmark.ORCID 0000-0001-5011-950X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAssessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. METHODS AND

findingsWe performed a cluster randomized controlled trial with randomization at the level of general practices (73 in each of two arms) in the Central Region (Region Midtjylland) of Denmark. In intervention practices, men were offered a genetic test (based on genotyping of 33 risk-associated single nucleotide polymorphisms) in addition to the standard PSA test that informed them about lifetime genetic risk of prostate cancer and distinguished between "normal" and "high" risk. The primary outcome was the proportion of men having a repeated PSA test within 2 years. A multilevel logistic regression model was used to test the association. After applying the exclusion criteria, 3,558 men were recruited in intervention practices, with 1,235 (34.7%) receiving the genetic test, and 4,242 men were recruited in control practices. Men with high genetic risk had a higher propensity for repeated PSA testing within 2 years than men with normal genetic risk (odds ratio [OR] = 8.94, p < 0.01). The study was conducted in routine practice and had some selection bias, which is evidenced by the relatively large proportion of younger and higher income participants taking the genetic test.

conclusionsProviding general practitioners (GPs) with access to a genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA tests. However, among men who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing.

trial registrationThis study is registered with ClinicalTrials.gov, number NCT01739062.

Indexed as

Genetic TestingAgedEarly Detection of CancerHumansKallikreinsLogistic ModelsMaleMiddle AgedMultilevel AnalysisPolymorphism, Single NucleotidePrimary Health CareProstate-Specific AntigenProstatic NeoplasmsRisk AssessmentKallikreinsKLK3 protein, humanProstate-Specific Antigen

Identifiers

PMID32032355
PMCPMC7006905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.